Evaluation of the Prevalence of Pelvic Static Disorders in Women With Localized Breast Cancer

Institut du Cancer de Montpellier - Val d'Aurelle246 enrolled

Overview

In this study, investigator propose to assess the prevalence of pelvic static disorders in women undergoing adjuvant hormone therapy for localized breast cancer and to assess the overall quality of life in these patients

Breast cancer is the most common cancer in women. Its incidence increases with 58,459 new cases in France in 2018, however its mortality decreases with a survival rate of 87% at 5 years. Therapeutic options are surgery, radiotherapy, chemotherapy and hormone therapy. Hormone therapy is one of the major treatments for hormone-sensitive tumors with a prescription made in around 70% of breast cancer cases. These different hormone therapies cause a hormonal imbalance with in particular an important anti-estrogenic action. Hormonal deprivation and menopause can be responsible for the occurrence of pelvic statics disorder.\[5-9\] Pelvic static disorder (PTS) is a common problem for women, which can occur at any age. These disorders include urinary incontinence, stress or urgency, anal incontinence, genital prolapse. Hypothesis's investigator is that hormone therapy may be responsible for PTS. In this study, investigator propose to assess the prevalence of pelvic static disorders in women undergoing adjuvant hormone therapy for localized breast cancer and to assess the overall quality of life in these patients.

Study Type

OBSERVATIONAL

Enrollment

246

Conditions

Breast Cancer

Interventions

PFDI-20 / PFIQ-7 questionnairesOTHER

PFDI-20 / PFIQ-7 questionnaires (one shot)

Eligibility

Sex: FEMALEMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women with Age ≥ 50 years * Menopaused * Patient followed for carcinoma in situ or infiltrating the breast with or without hormone therapy * Patient who was treated by surgery after June 2015, whether or not followed by radiotherapy or chemotherapy. * Patient who agreed, after receiving information, to participate to the study. Exclusion Criteria: * Metastatic breast cancer * Patient with a history of pelvic static surgery * Patient with a history of pelvic irradiation * Patient unable or unwilling to complete the questionnaires * Patient with a history of urinary incontinence treatment * Patient not affiliated to the French social security system * Subject under tutelage, curatorship or safeguard of justice, * Patient in an emergency situation, * Patient whose regular monitoring is impossible for psychological, family, social or geographical reasons, * Pregnant and / or breastfeeding woman.

Locations (1)

Icm Val D'Aurelle

Montpellier, Herault, France

Outcomes

Primary Outcomes

Evaluate the prevalence of pelvic static disorders in patients treated for localized breast cancer and undergoing adjuvant hormone therapy (Hormontherapy +).

Pelvic static disorders rate according to the Questionnaire on pelvic static disorders PFDI-20 in patients (hormonotherapy +)

Time frame: Day 1

Secondary Outcomes

Evaluate the prevalence of pelvic static disorders in patients (hormonotherapy -)

Pelvic static disorders rate according to the Questionnaire on pelvic static disorders PFDI-20 in patients hormonotherapy -

Time frame: Day 1

Compare the prevalence of Pelvic static disorders between the 2 groups Hormonotherapy - /Hormonotherapy +

Pelvic static disorders rate according to the Questionnaire on pelvic static disorders PFDI-20 in patients hormonotherapy - and patient hormontherapy +

Time frame: Day 1

Evaluate the impact of pelvic static disorders on quality of life

Estimation of quality of life according to the PFIQ-7 (Pelvic Floor Impact Questionnaire) in the 2 populations. the total score of the PFIQ-7 is obtained by adding the scores for each scale (between 0 (no impact) and 300 (maximum impact))

Time frame: Day 1

Estimate pelvic symptoms in the hormone therapy (Hormonotherapy +) / Non hormone therapy (Hormonotherapy -) groups

Estimation of pelvic symptoms scores according to the PFDI-20 (Pelvic Floor Distress Inventory) questionnaire in the 2 populations. the total score of the PFDI-20 is obtained by adding the scores for each scale (between 0 (no impact) and 300 (maximum impact))

Time frame: Day 1

Evaluate the correlation between hormone therapy and pelvic static disorders

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.